Heart Failure

How the effective cardiovascular drug class have reach a state of impending head-to-head trials.

A system which rewards hospitals based on their patient readmission rates may not be considering other factors of care.

A prospective study found that daily dapagliflozin significantly improved mitral flow, left ventricular mass index, and left atrial volume index after 6 months of treatment.

No head-to-head trials exist for the inhibitors, but current data shows consistency across the board for each drug.

Patients who received a flu shot had a lower rate of myocardial infarction, according to new research.

Recently new therapy options are becoming more evidenced by the day. But have they reached their fullest potential?

The Acticor and Rivacor brands from BIOTRONIK have become the smallest, slimmest 3 Tesla MR-conditional CRM devices on the US market.

Originally approved in 2013, the MitraClip is now approved for treating certain cases of secondary mitral regurgitation.

Recalls on Diovan (valsartan) began last July when the FDA detected trace amounts of a probable carcinogen in certain lots of the blood pressure drug.

The investigators also examined patients who had 3 or more injections in the year prior to their cardiac event.

The CAROLINA cardiovascular safety study found that linagliptin was non-inferior to glimepiride in time to a composite cardiovascular endpoint.

Since 2016, the health system has practiced a heart failure readmission reduction program that's improving patient quality of life.

Investigators suggest the findings mean anticoagulants or antiplatelets could potentially treat migraine patients with aura.

Heart patients discharged from the hospital with an opioid prescription were less likely to participate in planned follow-up care than those without prescribed opioids.